Phosphoproteomic and RNA-seq analysis was applied to NB cell lines treated with either crizotinib or lorlatinib, the first- and third-generation ALK inhibitors, identifying many differentially phosphorylated components of the ALK signaling pathway [105]. Here, ALK is linked to neuroblastoma.